Intuitive Surgical Reports Strong Growth Amid Valuation Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ISRG?
Source: Fool
Intuitive Surgical's stock fell 3.49% as it hit a 20-day low, reflecting broader market weakness with the Nasdaq-100 down 1.31% and S&P 500 down 1.09%.
Despite reporting a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, and a full-year revenue rise of 21% to $10.1 billion, the company faces high valuation risks with a price-to-earnings ratio of about 63. Management's cautious outlook for 2026, expecting a slowdown in da Vinci procedures growth to 13%-15%, has raised concerns among investors, contributing to the stock's decline amid overall market pressures.
The implications of Intuitive Surgical's strong revenue growth are overshadowed by the deceleration in growth expectations and high valuation risks, which could lead to increased volatility in its stock price moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 452.775
Low
575.00
Averages
637.32
High
740.00
Current: 452.775
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Analysis of SSO ETF's 52-Week Price Range
- Price Range Analysis: The SSO ETF's 52-week low is $30.42 per share, with a high of $60.37, and the latest trade at $53.24 indicates relative stability and investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), which can influence the performance of the underlying stocks held within the ETFs.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Analysis of SSO ETF's 52-Week Price Range
- Price Range Analysis: The SSO ETF's 52-week low is $30.42 per share, with a high of $60.37, and the latest trade at $53.24 indicates relative stability and investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), which can influence the performance of the underlying stocks held within the ETFs.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
